4.7 Article

RAD18 promotes the migration and invasion of esophageal squamous cell cancer via the JNK-MMPs pathway

Journal

CANCER LETTERS
Volume 417, Issue -, Pages 65-74

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2017.12.034

Keywords

RAD18; Esophageal squamous cell cancer; Metastasis; c-Jun N-Terminal kinase; DNA translesion synthesis

Categories

Funding

  1. National Natural Science Foundation of China [81372433, 1672975, 81573079]
  2. Jiangsu Provincial Medical Youth Talent [QNRC2016235]
  3. Six Talent Peaks Project of Jiangsu Province of China [WSN095]
  4. 333Project of Jiangsu Province of China [BRA2016071]
  5. Suzhou Administration of Science Technology [SYS201430, SYS201571]
  6. Suzhou Key Medical Center [SZZX201506]

Ask authors/readers for more resources

As a key regulator of DNA translesion synthesis (TLS) pathway, RAD18 is error-prone and contributes to the accumulation of DNA mutations. We have recently shown that RAD18 is overexpressed in human esophageal squamous cell cancer (ESCC) and acts to promote ESCC progression. The current study aims to understand the molecular mechanism by which RAD18 enhances the invasiveness and metastasis of ESCC cells. We found that RAD18 expression is markedly higher in high T stage ESCCs compared to low T stage groups. Kaplan-Meier analysis showed an inverse correlation between RAD18 expression and patient prognosis. The expression of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9), two vital mediators of cell invasion and proliferation, positively correlated with RAD18 expression in ESCC tissues. Ectopic expression of RAD18 enhanced the motility and invasiveness of ESCC cells as evaluated by wound-healing assays and transwell assays. A xenograft nude mouse model showed that RAD18 promoted the colonization of ESCC cells in vivo. Signaling pathway analysis identified the JNK-MMP cascade as a mediator of RAD18-induced enhancement of ESCC progression. These data demonstrate the underlying mechanism by which RAD18 promotes ESCC progression; suggesting that RAD18 is a promising novel prognostic biomarker and therapeutic target against ESCC. (C) 2018 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available